KRAS-Targeted Therapy Fighting Uphill

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, driving in numerous cancer types including non-small-cell lung cancer (NSCLC). KRAS is considered a undruggable target due to lack of classic drug binding sites. Over the last few years, great efforts have been made to explore routes for indirect targeting of KRAS mutant cancers. Scientists has found ways to drug KRAS-mutated cancers. FDA has approved an allele-specific covalent inhibitor of KRAS (G12C), AMG510 (sotorasib) from Amgen, which was a giant step for oncology.

ACROBiosystems has developed a series of KRAS proteins, which can be used for screening and validation of small-molecule inhibitors and PROTACs in vitro, and accelerating related drug development.

The purity of Human KRAS (2-185,G12D), His Tag (Cat. No. KRS-H51H4) is more than 90% and the molecular weight of this protein is around 24-34 kDa verified by SEC-MALS.